Skip to main content
Terug
DXCM logo

DexCom, Inc.

Datakwaliteit: 100%
DXCM
NASDAQ Healthcare Medical - Devices
€ 66,60
▲ € 0,66 (1,00%)
Marktkapitalisatie: 25,98B
Dagbereik
€ 65,10 € 66,93
52-Weeksbereik
€ 54,11 € 89,98
Volume
3.515.949
50D / 200D Gem.
€ 70,43 / € 72,55
Vorige Slotkoers
€ 65,94

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek Aandeel Sector Mediaan
P/E 31,1 0,3
P/B 9,5 2,9
ROE % 34,5 3,7
Net Margin % 17,9 3,8
Rev Growth 5Y % 17,5 10,0
D/E 0,5 0,2

Koersdoel Analisten

Hold
€ 85,82 +28.9%
Low: € 72,00 High: € 95,00
Forward K/W
26,5
Forward WPA
€ 2,49
WPA Groei (sch.)
+0,0%
Omzet Sch.
5,2 B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 4,87
€ 4,78 – € 5,07
 8,4 B 2
FY2029 € 4,19
€ 4,11 – € 4,36
 7,4 B 4
FY2028 € 3,57
€ 3,19 – € 3,97
 6,6 B 6

Belangrijkste Punten

Revenue grew 17,47% annually over 5 years — strong growth
Earnings grew 45,14% over the past year
ROE of 34,50% indicates high profitability
Net margin of 17,94% shows strong profitability
Generating 1,08B in free cash flow
P/E of 31,06 — premium valuation

Groei

Revenue Growth (5Y)
17,47%
Revenue (1Y)15,60%
Earnings (1Y)45,14%
FCF Growth (3Y)45,06%

Kwaliteit

Return on Equity
34,50%
ROIC16,54%
Net Margin17,94%
Op. Margin19,56%

Veiligheid

Debt / Equity
0,51
Current Ratio1,88
Interest Coverage0,00

Waardering

P/E Ratio
31,06
P/B Ratio9,46
EV/EBITDA29,01
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 15,60% Revenue Growth (3Y) 13,45%
Earnings Growth (1Y) 45,14% Earnings Growth (3Y) 24,27%
Revenue Growth (5Y) 17,47% Earnings Growth (5Y) 40,13%
Profitability
Revenue (TTM) 4,66B Net Income (TTM) 836,30M
ROE 34,50% ROA 13,19%
Gross Margin 60,10% Operating Margin 19,56%
Net Margin 17,94% Free Cash Flow (TTM) 1,08B
ROIC 16,54% FCF Growth (3Y) 45,06%
Safety
Debt / Equity 0,51 Current Ratio 1,88
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio 31,06 P/B Ratio 9,46
P/S Ratio 5,57 PEG Ratio 0,66
EV/EBITDA 29,01 Dividend Yield 0,00%
Market Cap 25,98B Enterprise Value 26,45B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 4,66B 4,03B 3,62B 2,91B 2,45B
Net Income 836,30M 576,20M 541,50M 341,20M 216,90M
EPS (Diluted) 2,09 1,42 1,30 0,80 0,51
Gross Profit 2,80B 2,44B 2,29B 1,88B 1,68B
Operating Income 911,80M 600,00M 597,70M 391,20M 265,80M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6,34B 6,48B 6,26B 5,39B 4,93B
Total Liabilities 3,59B 4,38B 4,20B 3,26B 2,89B
Shareholders' Equity 2,75B 2,10B 2,07B 2,13B 2,04B
Total Debt 1,39B 2,59B 2,59B 2,15B 2,16B
Cash & Equivalents 917,70M 606,10M 566,30M 642,30M 1,05B
Current Assets 4,03B 4,30B 4,43B 3,67B 3,68B
Current Liabilities 2,14B 2,93B 1,56B 1,84B 720,80M

Strategiescores

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Cash Flow Compounder
#757 of 1052
34
Custom Capital Light Compounder
#184 of 218
25
Growth Growth Investing (Philip Fisher)
#141 of 157
28
Custom Balanced Risk
#23 of 151
60
Custom Lower Risk
#26 of 140
55

Recente Activiteit

Ingestapt Cash Flow Compounder
Mar 24, 2026
Ingestapt Capital Light Compounder
Mar 24, 2026
Ingestapt Growth Investing (Philip Fisher)
Mar 24, 2026
Ingestapt Balanced Risk
Mar 24, 2026
Ingestapt Lower Risk
Mar 24, 2026